Neuroblastoma is composed of biologically varied tumors. This book provides an extensive analysis into the current prevalence of the disease and its future treatment modalities. Genomic/molecular properties exclusive to the specific tumors firmly link to the clinical results of patients. Formulation of risk stratification models post the analysis of biological characteristics of every case has resulted in huge success in patient management. Nevertheless, the trend of enhancing survival rates in this disease over the past 30 years has begun to level off, and presently available treatment options have nearly reached their maximized intensity. Moreover, aggressive treatment causes serious morbidities to the survivors. The book encompasses valuable data and insights from the world's experts in this field. It will serve as a great source of reference for all the investigators working hard and struggling for the children affected by this disease.